JTEKT CORPORATION V. GKN AUTOMOTIVE LTD.
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summary
Before Prost, Dyk, and O’Malley. Appeal from the Patent and Trial Appeal Board.
Summary: An IPR petitioner lacks standing to appeal an adverse decision by the Board if it sells no infringing products and there is no risk of future infringement or infringement allegations by the patentee.
JTEKT petitioned for IPR of a patent owned by GKN. The Board found some, but not all, of the claims obvious. JTEKT appealed.
The Federal Circuit held JTEKT lacked Article III standing. Although an IPR petitioner need not show an injury in fact to file for IPR, it must do so to appeal an adverse decision to the Federal Circuit. Because JTEKT was not selling infringing goods, JTEKT had to establish “concrete plans for future activity that create[] a substantial risk of future infringement or likely cause the patentee to assert a claim of infringement.” JTEKT could not meet this burden because it had not finalized its product design and, at most, GKN’s patent posed an unspecified risk to “future development.” The Federal Circuit also rejected JTEKT’s argument that IPR estoppel constitutes a separate injury in fact.
This case is: JTEKT CORPORATION V. GKN AUTOMOTIVE LTD.
Edited by: Paul Stewart
Written by: Forrest M. McClellen and Adam Powell
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…